Ness Ziona, Israel, November 3, 2005 --- Foamix Ltd.  announced today that company’s executive director, Dr. Stanley Hirsch, will speak at Bio–Europe 2005, at the International Congress Center in Dresden, Germany, on November 8^th at 8:30 a.m. in Room #5, Level 4. Dr. Hirsch’s presentation, Foamix - Innovative Delivery in Dermatology, is part of the delivery section of the program.

“Foamix is changing the face of dermatology. Foam offers the most convenient, easily applied, non-irritating way of effectively treating skin ailments. In addition, Foamix foams are able to deliver just about any active, and in comparably higher concentrations. And, it appears that pharma has taken note. In the last six months, we have signed agreements with three major international pharmaceutical companies to develop new foam products. One of these companies is Stiefel Laboratories, with whom we are developing a foam drug for scabies. We also found tremendous support of our R&D efforts at the recent October 2005 meeting of the European Academy of Dermatology,” said Dr. Hirsch.

“I am looking forward to demonstrating the benefits of the Foamix product line at Bio-Europe 2005 and to opening dialogues with companies interested in pursuing a mutually lucrative opportunity,” Dr. Hirsch added.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, non-flammable, stable foam products for prescription, Over-the-Counter and cosmetic uses. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The Company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing and clinical supplies. The Company was founded in January 2003 by CEO Dr. Dov Tamarkin, COO Mr. Meir Eini and Chief Technology Officer Dr. Doron Friedman. The Company employs 24 people and has 22 patents pending. In addition, Foamix recently received three U.S. patent approvals for its OilGel™ topical delivery platform. Foamix Ltd. is a pre-IPO, privately held company.

For additional information: Marjie Hadad, Media Liaison, Marjie@foamix.co.il or +972-54-536-5220.